白细胞介素-2（IL-2）市场（2026—2031）
白细胞介素-2（IL-2）市场规模预计由2026年的17.8亿美元增至2031年的24.4亿美元，预测期复合年增长率为6.50%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
白细胞介素-2（IL-2）市场规模预计由2026年的17.8亿美元增至2031年的24.4亿美元，预测期复合年增长率为6.50%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 6.5% | 机构预测 |
| 市场规模 | 2026 | USD 1.78 billion | 机构预测 |
| 市场规模 | 2031 | USD 2.44 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| end_user | hospitals and clinics | 2025 | 65.780% |
| geography | North America | 2025 | 39.340% |
| indication | melanoma | 2025 | 35.660% |
| product_type | aldesleukin | 2025 | 65.450% |
| route_of_administration | intravenous delivery | 2025 | 88.650% |
关键结论
- end_user 维度中，hospitals and clinics 在 2025 年的公开份额为 65.78%。
- geography 维度中，North America 在 2025 年的公开份额为 39.34%。
- indication 维度中，melanoma 在 2025 年的公开份额为 35.66%。
- product_type 维度中，aldesleukin 在 2025 年的公开份额为 65.45%。
- route_of_administration 维度中，intravenous delivery 在 2025 年的公开份额为 88.65%。
主要参与者
- Iovance Biotherapeutics, Inc.
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Nektar Therapeutics
- Innovent Biologics, Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Expansion of IL-2 use in tumor-infiltrating lymphocyte therapy | +1.400% | Global, with the greatest effect in North America and Europe at leading lifileucel treatment centers | Medium term (2-4 years) |
| Growth of engineered IL-2 receptor-biased therapies | +1.600% | Global, with early uptake in North America and expansion through clinical trial networks in Asia-Pacific and Europe | Long term (≥ 4 years) |
| Increasing adoption of IL-2 and checkpoint inhibitor combinations | +1.200% | North America and Europe, with rapid growth in Asia-Pacific | Medium term (2-4 years) |
| Rising demand for low-dose IL-2 in autoimmune disease | +0.900% | China-led activity in Asia-Pacific, with development also in North America and Europe | Long term (≥ 4 years) |
| Treg-directed immunotherapy for immune-tolerance restoration | +0.700% | North America and the European Union, where chronic autoimmune disease has high unmet need | Long term (≥ 4 years) |
| IL-2 demand from decentralized and self-administered formulations | +0.600% | Global, especially Europe and North America with established hub-and-spoke oncology care | Short term (≤ 2 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High-Dose IL-2 toxicity and intensive-care requirements | -0.800% | Global, with the strongest effect in South America and the Middle East and Africa where ICU oncology capacity is limited | Short term (≤ 2 years) |
| Short half-life and frequent dosing of conventional aldesleukin | -0.500% | Global, with stronger pressure in Asia-Pacific and Europe where outpatient protocols are prioritized | Medium term (2-4 years) |
| Substitution from checkpoint inhibitors and other immunotherapies | -0.700% | North America and Europe, where checkpoint inhibitor use is highest | Medium term (2-4 years) |
| Limited reimbursement alignment for complex IL-2-based treatment pathways | -0.400% | Global, with a clear gap in European systems for multi-agent oncology pricing | Long term (≥ 4 years) |
报告关注的关键问题
What is the expected value of the Interleukin-2 market by 2031?
The Interleukin-2 market is forecast to reach USD 2.44 billion by 2031, from USD 1.78 billion in 2026, at a 6.50% CAGR.
Which Interleukin-2 product type has the largest revenue position?
Aldesleukin held 65.45% of product revenue in 2025, supported by its established use in oncology care.
Which treatment area is growing fastest for IL-2 therapies?
Renal cell carcinoma is projected to grow at an 8.56% CAGR through 2031, supported by combination data with pembrolizumab and high-dose IL-2.
Why are engineered IL-2 products being developed?
These products seek to stimulate effector T cells and natural killer cells while reducing CD25 signaling and the vascular toxicity associated with conventional therapy.
How are subcutaneous formulations changing IL-2 treatment?
Subcutaneous administration is forecast to grow at a 7.44% CAGR through 2031 and can support shorter treatment time and more outpatient care.
Which region is expanding fastest for IL-2 therapies?
Asia-Pacific is forecast to grow at an 8.45% CAGR through 2031, with China contributing 40% to 45% of regional demand in 2026, supporting regional expansion in the Interleukin-2 market.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence